Our results suggested that Treg/CD8+ T cells expressing CD39, CTLA-4, TNFR2, TIGIT, and TIM-3 favor B-ALL progression, and targeted immunotherapy against these markers could be a promising approach for treating B-ALL. The gene discussed is HAVCR2; the disease is precursor B-cell acute lymphoblastic leukemia.